High throughput generation of a resource of the human secretome in mammalian cells.


Journal

New biotechnology
ISSN: 1876-4347
Titre abrégé: N Biotechnol
Pays: Netherlands
ID NLM: 101465345

Informations de publication

Date de publication:
25 Sep 2020
Historique:
received: 12 03 2020
revised: 04 05 2020
accepted: 30 05 2020
pubmed: 6 6 2020
medline: 15 12 2020
entrez: 6 6 2020
Statut: ppublish

Résumé

The proteins secreted by human tissues and blood cells, the secretome, are important both for the basic understanding of human biology and for identification of potential targets for future diagnosis and therapy. Here, a high-throughput mammalian cell factory is presented that was established to create a resource of recombinant full-length proteins covering the majority of those annotated as 'secreted' in humans. The full-length DNA sequences of each of the predicted secreted proteins were generated by gene synthesis, the constructs were transfected into Chinese hamster ovary (CHO) cells and the recombinant proteins were produced, purified and analyzed. Almost 1,300 proteins were successfully generated and proteins predicted to be secreted into the blood were produced with a success rate of 65%, while the success rates for the other categories of secreted proteins were somewhat lower giving an overall one-pass success rate of ca. 58%. The proteins were used to generate targeted proteomics assays and several of the proteins were shown to be active in a phenotypic assay involving pancreatic β-cell dedifferentiation. Many of the proteins that failed during production in CHO cells could be rescued in human embryonic kidney (HEK 293) cells suggesting that a cell factory of human origin can be an attractive alternative for production in mammalian cells. In conclusion, a high-throughput protein production and purification system has been successfully established to create a unique resource of the human secretome.

Identifiants

pubmed: 32502629
pii: S1871-6784(20)30132-1
doi: 10.1016/j.nbt.2020.05.002
pii:
doi:

Substances chimiques

Recombinant Proteins 0
DNA 9007-49-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

45-54

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Hanna Tegel (H)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Melanie Dannemeyer (M)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Sara Kanje (S)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Åsa Sivertsson (Å)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden; Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.

Anna Berling (A)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Anne-Sophie Svensson (AS)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Andreas Hober (A)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden; Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.

Henric Enstedt (H)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Anna-Luisa Volk (AL)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Magnus Lundqvist (M)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Mona Moradi (M)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Delaram Afshari (D)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Siri Ekblad (S)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

LanLan Xu (L)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Malin Westin (M)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Faranak Bidad (F)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Lovisa Holmberg Schiavone (LH)

Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Rick Davies (R)

Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.

Lorenz M Mayr (LM)

Syncona Investment Ltd, London, UK; ETH Zurich, B-BIOL, Molecular Health Sciences, Zurich, Switzerland.

Sinead Knight (S)

Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.

Sven O Göpel (SO)

Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceutical R&D, AstraZeneca, Gothenburg, Sweden.

Björn G Voldborg (BG)

Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Denmark.

Fredrik Edfors (F)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden; Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.

Björn Forsström (B)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden; Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.

Kalle von Feilitzen (K)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden; Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.

Martin Zwahlen (M)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden; Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.

Johan Rockberg (J)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Jenny Ottosson Takanen (JO)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.

Mathias Uhlén (M)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden; Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden; Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Denmark.

Sophia Hober (S)

Department of Protein Science, School of Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden. Electronic address: sophia@kth.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH